AveXis company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

avexis.com

Founded Year

2012

Stage

Acq - P2P | Acquired

Total Raised

$75M

Valuation

$0000 

About AveXis

AveXis is a clinical-stage gene therapy company developing treatments for rare and life-threatening neurological genetic diseases. The company's initial product candidate, scAAV9.CB.SMN, is in an ongoing Phase 1 clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, an autosomal-recessive genetic disorder characterized by lower motor neuron loss and progressive muscle weakness. SMA is caused by a genetic defect in the SMN1 gene that codes SMN, a protein necessary for the survival of motor neurons. SMA Type 1 is the most common cause of infant mortality and is the second-most common autosomal recessive genetic disorder.

AveXis Headquarter Location

2275 Half Day Road Suite 160

Deerfield, Illinois, 60015,

United States

847-572-8280

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AveXis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AveXis is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Latest AveXis News

Sumo Logic Appoints John D. Harkey, Jr. to Board of Directors

May 3, 2022

By Reading Time: 4 minutes REDWOOD CITY, Calif., May 03, 2022 (GLOBE NEWSWIRE) — Sumo Logic (Nasdaq: SUMO), the SaaS analytics platform to enable reliable and secure cloud-native applications, today announced that it has appointed John D. Harkey, Jr. to its Board of Directors, effective immediately. With this addition, the Sumo Logic Board will consist of ten directors, eight of whom are independent. The appointment of Mr. Harkey is part of a mutual cooperation agreement (“the agreement”) with Scalar Gauge Fund, L.P. (“Scalar Gauge”). Additionally, Sumo Logic has agreed with Scalar Gauge to collaborate on an ongoing process aimed at identifying and appointing an additional director. “We are looking forward to working with John,” said Ramin Sayar, President and CEO of Sumo Logic. “John brings over 25 years of experience as a private investor and chief executive, in both public and private companies across a wide range of industries. Sumo Logic has strong momentum with accelerating revenue growth backed by a refreshed and best in class go-to-market strategy. We welcome John’s fresh perspective on the Company’s operations and strategy to drive profitable growth and stockholder value.” “We’re pleased to have worked constructively with the Sumo Logic Board to reach this understanding with the Company and believe adding John to the Board will contribute to unlocking the tremendous value in the business,” commented Sumit Gautam, Founder and Portfolio Manager of Scalar Gauge. “Sumo Logic has differentiated products that customers love and we look forward to seeing the Company continue to execute on opportunities to drive profitable growth ahead. We are confident that John’s experience can bring additional perspective and insight to the Board and management team.” Pursuant to the agreement, Mr. Harkey will be appointed to the Board’s Audit Committee and Compensation and Talent Committee. Scalar Gauge has agreed to customary standstill, voting, and other provisions. The full agreement between Sumo Logic and Scalar Gauge will be filed on a Form 8-K with the SEC. About John D. Harkey, Jr. John D. Harkey, Jr. is the Founder of JDH Investment Management, LLC. John is an entrepreneur, businessman and philanthropist and has served on the board of directors of eight (8) public companies in energy, aerospace, telecommunications, biotech and restaurants, and private companies in healthcare, animal health, farm and ranch products and software development. He is Co-Founder and formerly Executive Chairman of the Board of AveXis, Inc., which was acquired in 2018 by Novartis AG. AveXis develops proprietary gene therapies for Spinal Muscular Atrophy, a previously incurable children’s disease. He is also Chairman of the Board of Dialectic Therapeutics, Inc., which is developing cancer immunotherapies. He is also a Co-Founder and currently serves on the Board of Cessation Therapeutics, a developer of vaccines for addictions to fentanyl, heroin and nicotine. He serves on the Board of Directors of Durvet, Inc., one of the nation’s largest distributors of animal healthcare products. He also serves on the boards of MD Anderson Cancer Center, Baylor Healthcare Foundation, the State Fair of Texas, the Dallas Arboretum and the Circle Ten Council of the Boy Scouts of America. He was a lead investor and served on the Board of CerSci Therapeutics, which has a primary compound for a non-opioid severe pain reliever. CerSci was acquired in 2020 by Acadia Pharmaceuticals. He is formerly the Chairman of the Board of Regency Gas Partners, L.P. and has served on the Board of Directors of the Energy Transfer LP companies. He formerly served on the Board of Directors of Loral Space & Communications, Inc., which merged with Telesat, and on the Board of Directors of Emisphere Technologies, Inc. which was acquired by Novo Nordisk, and formerly served on Board of Directors of Leap Wireless International, Inc., which was acquired by AT&T. About Sumo Logic Sumo Logic, Inc. (Nasdaq: SUMO) empowers the people who power modern, digital business. Through its SaaS analytics platform, Sumo Logic enables customers to deliver reliable and secure cloud-native applications. The Sumo Logic Continuous Intelligence Platform™ helps practitioners and developers ensure application reliability, secure and protect against modern security threats, and gain insights into their cloud infrastructures. Customers around the world rely on Sumo Logic to get powerful real-time analytics and insights across observability and security solutions for their cloud-native applications. For more information, visit www.sumologic.com . About Scalar Gauge Fund Scalar Gauge Fund is a special situations investment firm utilizing a private equity approach in public markets. The fund invests with a long-term view, and often works with management teams, boards and other strategic investors to help create shareholder value. For more information, please visit www.scalargauge.com . Forward-Looking Statements This press release contains expressed and implied forward-looking statements including but not limited to expectations regarding the benefits of our offerings, our growth strategy and investments, and our ability to achieve success. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to our ability to achieve and maintain future profitability, our ability to sustain and manage our growth, our ability to successfully add new features and functionality to our platform, our ability to compete effectively in an increasingly competitive market, general market, political, economic and business conditions, and other risks detailed in our Annual Form 10-K for the year ended January 31, 2022 filed with the SEC on March 14, 2022, which should be read in conjunction with this press release. Past performance is not necessarily indicative of future results. The forward-looking statements included in this press release represent our views as of the date of this press release. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. We anticipate that subsequent events and developments could cause our views to change. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Media Contacts:

  • When was AveXis founded?

    AveXis was founded in 2012.

  • Where is AveXis's headquarters?

    AveXis's headquarters is located at 2275 Half Day Road, Deerfield.

  • What is AveXis's latest funding round?

    AveXis's latest funding round is Acq - P2P.

  • How much did AveXis raise?

    AveXis raised a total of $75M.

  • Who are the investors of AveXis?

    Investors of AveXis include Novartis, Roche Venture Fund, Deerfield Management, Venrock, Janus Capital Group and 13 more.

  • Who are AveXis's competitors?

    Competitors of AveXis include CODA Biotherapeutics and 1 more.

You May Also Like

Renova Therapeutics Logo
Renova Therapeutics

Renova Therapeutics is a San Diego-based biopharmaceutical company and an industry leader in gene therapy, pursuing the development of treatments for congestive heart failure (CHF) and other chronic diseases. CHF is the most rapidly growing cardiovascular disorder in the United States, with an estimated six million people afflicted and 550,000 new cases diagnosed every year. Approximately 26 million patients have CHF worldwide. Renova Therapeutics, in a Public-Private Partnership with the National Institutes of Health, is currently supporting a Phase I/II trial of its novel lead therapy for patients with severe CHF (Class II, III and IV). This initial product is a single-dose gene therapy that, in animal studies, has shown substantially improved, sustained outcomes in heart failure models by safely and significantly improving myocardial function. The product is being evaluated for its safety and initial efficacy in a 3:1 randomized, double-blinded, placebo-controlled dose-ranging study involving 56 patients across seven US medical centers.

S
StrideBio

StrideBio is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) vector technologies. The company is building a proprietary therapeutic pipeline focused on rare diseases.

A
AAVLife

AAVLife, registered in Paris, is a privately held company dedicated to advancing gene therapy for rare diseases. AAVLife's lead indication is for Friedreich's Ataxia Cardiomyopathy. Its program is based on the successful use of a gene-therapy approach in a mouse model developed to mimic the gene defect and cardiac symptoms of Friedreich's Ataxia. The approach made use of an adeno-associated virus (AAV) to introduce a normal gene into cardiac tissue. The therapy restored cardiac function and reversed pathological heart enlargement in mice that had already progressed to heart failure.

R
Redpin Therapeutics

Redpin Therapeutics is a privately held, preclinical stage gene therapy company based in New York City. The company is developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Its approach integrates principles from synthetic biology, gene therapy, and traditional pharmacotherapy.

Neurogene Logo
Neurogene

Neurogene develops genetic medicines for patients and families affected by rare neurological diseases.

C
CODA Biotherapeutics

CODA Biotherapeutics is a preclinical-stage biopharmaceutical company developing a chemogenetic gene therapy platform for the treatment of intractable diseases. Its platform aims to control the activity of neurons to treat disease. With chemogenetics, target neuronal populations are modified using gene therapy to express a tunable ligand-gated ion channel. These ligand-gated ion channels are engineered to be highly responsive to a specific proprietary small molecule but are otherwise inactive. The interaction of the small molecule and engineered receptor allow for dose-dependent control of the neurons to generate therapeutic effect.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.